Estimated Familial Amyotrophic Lateral Sclerosis Proportion: A Literature Review and Meta-analysis.


Journal

Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 08 05 2023
accepted: 22 09 2023
medline: 4 12 2023
pubmed: 4 12 2023
entrez: 4 12 2023
Statut: epublish

Résumé

Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder. Familial (fALS) cases are usually reported to constitute 5%-10% of all ALS cases; however, no recent literature review or meta-analysis of this proportion (referred to throughout as "proportion fALS") has been conducted. Our objective was to estimate the proportion fALS by geographic region and to assess the effect of study characteristics on the estimates. A comprehensive literature review was performed to identify all original studies reporting the number of fALS cases in an ALS cohort. The results were stratified by geographic region, study design (case series or population-based), and decade of study publication. Subgroup analyses were conducted according to family history criteria used to define fALS. We report pooled estimates of the proportion fALS from random-effects meta-analyses when >2 studies are available and I The overall pooled proportion fALS based on a total 165 studies was 8% (0%, 71%). The proportion fALS was 9% (0%, 71%) among 107 case series and 5% (4%, 6%) among 58 population-based studies. Among population-based studies, proportion fALS by geographic region was 6% (5%, 7%; N = 37) for Europe, 5% (3%, 7%; N = 5) for Latin America, and 5% (4%, 7%; N = 12) for North America. Criteria used to define fALS were reported by 21 population-based studies (36%), and proportion fALS was 5% (4%, 5%; N = 9) for first-degree relative, 7% (4%, 11%; N = 4) for first or second-degree relative, and 11% (N = 1) for more distant ALS family history. Population-based studies published in the 2000s or earlier generated a lower pooled proportion fALS than studies published in the 2010s or later. The results suggest that variability in the reported proportion fALS in the literature may be, in part, due to the differences in geography, study design, fALS definition, and decade of case ascertainment. Few studies outside of European ancestral populations were available. The proportion fALS was marginally higher among case series compared with population-based studies, likely because of referral bias. Criteria used to define fALS were largely unreported. Consensus criteria for fALS and additional population-based studies in non-European ancestral populations are needed.

Sections du résumé

Background and Objectives UNASSIGNED
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder. Familial (fALS) cases are usually reported to constitute 5%-10% of all ALS cases; however, no recent literature review or meta-analysis of this proportion (referred to throughout as "proportion fALS") has been conducted. Our objective was to estimate the proportion fALS by geographic region and to assess the effect of study characteristics on the estimates.
Methods UNASSIGNED
A comprehensive literature review was performed to identify all original studies reporting the number of fALS cases in an ALS cohort. The results were stratified by geographic region, study design (case series or population-based), and decade of study publication. Subgroup analyses were conducted according to family history criteria used to define fALS. We report pooled estimates of the proportion fALS from random-effects meta-analyses when >2 studies are available and I
Results UNASSIGNED
The overall pooled proportion fALS based on a total 165 studies was 8% (0%, 71%). The proportion fALS was 9% (0%, 71%) among 107 case series and 5% (4%, 6%) among 58 population-based studies. Among population-based studies, proportion fALS by geographic region was 6% (5%, 7%; N = 37) for Europe, 5% (3%, 7%; N = 5) for Latin America, and 5% (4%, 7%; N = 12) for North America. Criteria used to define fALS were reported by 21 population-based studies (36%), and proportion fALS was 5% (4%, 5%; N = 9) for first-degree relative, 7% (4%, 11%; N = 4) for first or second-degree relative, and 11% (N = 1) for more distant ALS family history. Population-based studies published in the 2000s or earlier generated a lower pooled proportion fALS than studies published in the 2010s or later.
Discussion UNASSIGNED
The results suggest that variability in the reported proportion fALS in the literature may be, in part, due to the differences in geography, study design, fALS definition, and decade of case ascertainment. Few studies outside of European ancestral populations were available. The proportion fALS was marginally higher among case series compared with population-based studies, likely because of referral bias. Criteria used to define fALS were largely unreported. Consensus criteria for fALS and additional population-based studies in non-European ancestral populations are needed.

Identifiants

pubmed: 38045991
doi: 10.1212/NXG.0000000000200109
pii: NXG-2023-000153
pmc: PMC10689005
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e200109

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Déclaration de conflit d'intérêts

J. Barberio: employee of Epidemiologic Research & Methods, LLC, doctoral stipend and tuition are supported by an award to Emory University from Amgen Inc; C. Lally: employee of Epidemiologic Research and Methods; V. Kuplian: employee of and holds stock/stock options in Biogen; O. Hardiman: Science Foundation Ireland grants SFI 16/RC/3948 and 20/SP/8953, consulting fees from Cytokinetics, Wave Pharmaceuticals, Orion, Biogen, Denali, Novartis and Accelsior, Editor-in-Chief of the journal ALS and Frontotemporal Degeneration; W.D. Flanders: employee of Epidemiologic Research & Methods, LLC, employee of Rollins School of Public Health. Go to Neurology.org/NG for full disclosures.

Références

Nat Commun. 2017 Mar 21;8:14774
pubmed: 28322246
Lancet Neurol. 2022 May;21(5):465-479
pubmed: 35334234
J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):365-7
pubmed: 22399794
Eur J Neurol. 2015 Nov;22(11):1474-81
pubmed: 26176978
PLoS One. 2018 Apr 16;13(4):e0195821
pubmed: 29659621
Neurology. 2009 Feb 24;72(8):725-31
pubmed: 19237701
Lancet Neurol. 2018 Jan;17(1):94-102
pubmed: 29154141
Hum Hered. 2011;71(4):281-8
pubmed: 21846995
Brain. 2006 Apr;129(Pt 4):868-76
pubmed: 16495328
Neuroepidemiology. 2021;55(3):196-205
pubmed: 33902051
Neuron. 2011 Oct 20;72(2):257-68
pubmed: 21944779
Neurotoxicology. 2020 Dec;81:80-88
pubmed: 32941938
Nat Rev Neurol. 2013 Nov;9(11):617-28
pubmed: 24126629
J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):557-563
pubmed: 28285264
Genome Med. 2022 Mar 8;14(1):27
pubmed: 35260199
Eur J Hum Genet. 2021 Apr;29(4):604-614
pubmed: 33414559
Nat Rev Dis Primers. 2017 Oct 05;3:17071
pubmed: 28980624
J Neurol Sci. 1999 Jun;165 Suppl 1:S21-6
pubmed: 10448977
Neuroepidemiology. 2021;55(5):342-353
pubmed: 34247168
J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1133
pubmed: 22791902
J Neurol Sci. 1994 Jul;124 Suppl:96-107
pubmed: 7807156
Neurol Genet. 2018 May 18;4(3):e239
pubmed: 29845113
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct - Nov;17(7-8):535-542
pubmed: 27399231
Cerebellum. 2020 Jun;19(3):446-458
pubmed: 32086717
J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):623-7
pubmed: 21047878
Neurology. 1996 Aug;47(2):571-3
pubmed: 8757041
Neurology. 2017 Mar 7;88(10):991-999
pubmed: 28159885
Neurology. 2003 Mar 11;60(5):813-9
pubmed: 12629239
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Neuroepidemiology. 2013;41(2):118-30
pubmed: 23860588
Amyotroph Lateral Scler Frontotemporal Degener. 2021 Aug;22(5-6):401-409
pubmed: 33641502
Lancet Neurol. 2018 Dec;17(12):1083-1097
pubmed: 30409709
J Neurol. 2016 Oct;263(10):1919-26
pubmed: 27372451
J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):659-665
pubmed: 30846540
Lancet Neurol. 2010 Oct;9(10):995-1007
pubmed: 20864052
Int J Epidemiol. 2017 Feb 1;46(1):57-74
pubmed: 27185810
J Neurol. 2021 Aug;268(8):2973-2984
pubmed: 33630135
Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):885-9
pubmed: 16941654
Amyotroph Lateral Scler. 2011 May;12(3):157-9
pubmed: 21208036
Neurology. 2017 Jun 13;88(24):2321-2329
pubmed: 28515268
Lancet. 2011 Mar 12;377(9769):942-55
pubmed: 21296405
Nat Neurosci. 2014 Jan;17(1):17-23
pubmed: 24369373
Arch Neurol. 2012 Nov;69(11):1410-6
pubmed: 22892641
J Neurol. 2017 Jun;264(6):1091-1098
pubmed: 28444446
Ann Neurol. 2015 Jan;77(1):100-13
pubmed: 25382069
Neuroepidemiology. 2016;46(2):96-105
pubmed: 26731747
Nat Commun. 2016 Aug 11;7:12408
pubmed: 27510634
J Neurol. 2021 Oct;268(10):3766-3776
pubmed: 33770234

Auteurs

Julie Barberio (J)

From the Epidemiologic Research and Methods LLC (J.B., C.L., W.D.F.); Rollins School of Public Health (J.B., W.D.F.), Emory University, Atlanta, GA; Biogen (V.K.), Cambridge, MA; and Trinity Biomedical Sciences Institute (O.H.), Dublin, Ireland.

Cathy Lally (C)

From the Epidemiologic Research and Methods LLC (J.B., C.L., W.D.F.); Rollins School of Public Health (J.B., W.D.F.), Emory University, Atlanta, GA; Biogen (V.K.), Cambridge, MA; and Trinity Biomedical Sciences Institute (O.H.), Dublin, Ireland.

Varant Kupelian (V)

From the Epidemiologic Research and Methods LLC (J.B., C.L., W.D.F.); Rollins School of Public Health (J.B., W.D.F.), Emory University, Atlanta, GA; Biogen (V.K.), Cambridge, MA; and Trinity Biomedical Sciences Institute (O.H.), Dublin, Ireland.

Orla Hardiman (O)

From the Epidemiologic Research and Methods LLC (J.B., C.L., W.D.F.); Rollins School of Public Health (J.B., W.D.F.), Emory University, Atlanta, GA; Biogen (V.K.), Cambridge, MA; and Trinity Biomedical Sciences Institute (O.H.), Dublin, Ireland.

W Dana Flanders (WD)

From the Epidemiologic Research and Methods LLC (J.B., C.L., W.D.F.); Rollins School of Public Health (J.B., W.D.F.), Emory University, Atlanta, GA; Biogen (V.K.), Cambridge, MA; and Trinity Biomedical Sciences Institute (O.H.), Dublin, Ireland.

Classifications MeSH